Leslie Jones, MD
Ophthalmology · Washington, DCNPI 1790894772
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. AbbVie accounts for 74.9% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $11,050 and has fallen 83.6% since, to $1,815 in 2025. Among ophthalmology clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $129.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$16K
- Alcon$736
- Aerie Pharmaceuticals, Inc.$534
- Sight Sciences, Inc.$523
- Bausch & Lomb Americas Inc.$515
- Glaukos Corporation$430
- plus $3K from 20 others
Across 6 payments — averaging $2689.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$16K
What the payments were for
- Consulting fees$2,70012%
- Speaking & faculty fees$7,16733%
- Travel & lodging$1,9799%
- Food & beverage$9,47643%
- Education$2101%
- Gifts$390%
- Entertainment$2181%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 85 | $16,315 |
| Alcon | 12 | $736 |
| Aerie Pharmaceuticals, Inc. | 6 | $534 |
| Sight Sciences, Inc. | 7 | $523 |
| Bausch & Lomb Americas Inc. | 5 | $515 |
| Glaukos Corporation | 7 | $430 |
| Sun Pharmaceutical Industries Inc. | 5 | $347 |
| Shire North American Group Inc | 2 | $244 |
| NEW World Medical,inc. | 4 | $244 |
| Nova Eye, Inc. | 1 | $218 |
| Apellis Pharmaceuticals, Inc. | 2 | $217 |
| Ivantis, Inc | 1 | $184 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $155 |
| Dompe US, Inc. | 2 | $149 |
| Genentech USA, Inc. | 1 | $133 |
| Intuitive Surgical | 1 | $121 |
| Thea Pharma Inc. | 2 | $120 |
| ANI Pharmaceuticals, Inc. | 4 | $115 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $113 |
| Tarsus Pharmaceuticals, Inc. | 3 | $96 |
| Novartis | 4 | $89 |
| Amgen(2 entities) | 3 | $70 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Biotissue Holdings Inc. | 3 | $34 |
| Harrow Eye, LLC | 1 | $25 |
| Ocular Therapeutix, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN$9,512
- DURYSTA$2,944
- XEN GLAUCOMA TREATMENT SYSTEM$2,061
- LUMIGAN$1,719
- Rocklatan$705
- XIIDRA$468
- Rhopressa$441
- OMNI(R) SURGICAL SYSTEM (US)$382
- MIEBO$325
- Hydrus$184
- iAccess Precision Blade$158
- SIMBRINZA$148
- SUSVIMO$133
- RESTASIS MULTIDOSE$130
- OZURDEX$130
- Oxervate$121
- CEQUA$121
- Da Vinci Surgical System$121
- Syfovre$119
- VYZULTA$101
How this compares
$21,788 in reported general payments places this provider in the 90th percentile of 74 ophthalmology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 68 | $45,200 |
| RestasisCyclosporine | 34 | $42,193 |
| Restasis MultidoseCyclosporine | 34 | $32,212 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 48 | $17,696 |
| RocklatanNetarsudil Mesylat/Latanoprost | 21 | $13,119 |
| LumiganBimatoprost | 19 | $9,945 |
| VyzultaLatanoprostene Bunod | 18 | $9,133 |
| Alphagan PBrimonidine Tartrate | 24 | $8,153 |
| Brimonidine Tartrate | 102 | $7,376 |
| Cyclosporine | 11 | $5,330 |
| Brinzolamide | 32 | $4,530 |
| Travoprost | 22 | $4,145 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $3,264 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $2,858 |
| Prednisolone Acetate | 40 | $2,397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose, Lumigan, Alphagan P, Combigan | $16,315 | $95,360122 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $534 | $58,31989 claims |
| AlconSimbrinza | $736 | $17,69648 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $515 | $9,13318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 74 ophthalmology providers in District of Columbia.
Other ophthalmology in Washington
- Wiley ChambersWashington$618K
- Keesha Williams ElliottWashington$167K
- Samuel StopakWashington$33K
- Jonca BullWashington$30K
- Alexander HacopianWashington$13K
- Mehdi Tavakoli DastjerdiWashington$12K
- Andrew HammerWashington$11K
- Thandeka MyeniWashington$10K
- Dipak PanigrahiWashington$9K
- Jared EbertWashington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.